Skip to content
Contact
About PORTAL
Our Team
Our Work
Innovation Incentives and Competition
Regulation and Clinical Evidence
Price, Value, and Access
Search Our Library
Testimony: Congress Should Support Development of New Treatments for Pediatric Rare Diseases, But Not with Priority Review Vouchers
HOME
/
Policy Interactions
/
Testimony: Congress Should Support Development of New Treatments for Pediatric Rare Diseases, But Not with Priority Review Vouchers